Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Lymphatic Malformation
Interventions
BIOLOGICAL

TARA-002

All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.

Trial Locations (10)

19104

WITHDRAWN

Children's Hospital of Philadelphia: Comprehensive Vascular Anomalies Program, Philadelphia

20010

RECRUITING

Children's National Medical Center: Children's Research Institute, Washington D.C.

23507

RECRUITING

Children's Hospital of the King's Daughters, Norfolk

32207

RECRUITING

Nemours Children's Clinic - Jacksonville, Jacksonville

35294

RECRUITING

Children's Hospital of Alabama, Birmingham

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

72202

RECRUITING

Arkansas Children's Hospital/UAMS, Little Rock

88045

RECRUITING

Children's Hospital of Colorado, Aurora

97239

RECRUITING

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Protara Therapeutics

INDUSTRY